protein tyrosine phosphatase non-receptor type 18Genealiases: BDP1 · PTP-HSCF
Q-omics provides the consensus-scored PTPN18 profile across patient tissues and cancer cell-line models. PTPN18 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTPN18 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PTPN18 protein abundance shows 32,016 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where PTPN18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN18 survival associations across molecular data types. PTPN18 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN18 RNA expression–survival associations across cancer types. High PTPN18 expression shows unfavorable associations in ACC, UVM, LGG and COAD, but favorable associations in BRCA and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTPN18 RNA expression.
This table summarizes PTPN18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN18 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, STAD, LIHC and KIRP. The KIRC box plot shows higher PTPN18 RNA expression in tumor versus normal tissue (log2 FC = +0.790, t-test p < 0.001).
This table shows molecular features associated with PTPN18 in patient tissues and cancer cell lines. In patient samples, PTPN18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
